nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.03.2014 | Original Paper

Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML)

verfasst von: M. Philipp, J. Schwaab, C. T. Dietz, B. Hanfstein, L. Kalmanti, U. Munjal, M. Mossner, D. Nowak, W. Seifarth, W. K. Hofmann, A. Hochhaus, M. C. Müller, P. Erben

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Overexpression of transketolase-like gene 1 (TKTL1) on RNA and protein level has been linked to tumour progression, metastasis and unfavourable patient outcome in many solid tumours. Chronic myeloid leukaemia (CML) cells show metabolic characteristics resembling deviations observed in TKTL1 overexpressing solid tumour cells. We therefore sought to evaluate TKTL1 gene expression in different phases of CML.

Methods

A total of 120 peripheral blood samples from 69 patients in various phases of CML and 21 healthy individuals were investigated. TKTL1 expression levels were determined by real-time quantitative polymerase chain reaction using LightCycler™ technology and normalised against beta-glucuronidase expression.

Results

A significantly lower TKTL1 expression was found in chronic phase (CP) CML patients compared to healthy controls. Lowest expression levels were observed in patients during blast crisis (BC). Baseline TKTL1 expression in CP patients did not have value in prognostication of subsequent favourable or dismal outcome. Further, more mature granulocytes showed significantly higher TKTL1 expression compared to immature CD34+ and CD34−/CD33+ cells both in healthy controls and in CML patients.

Conclusion

TKTL1 expression levels appear to decline in the course of CML with lowest levels during BC. A potential reason is a shift of TKTL1-high-expressing mature granulocytes towards TKTL1-low-expressing immature cells and blasts.

Boren J, Cascante M, Marin S, Comin-Anduix B, Centelles JJ, Lim S, Bassilian S, Ahmed S, Lee WNP, Boros LG (2001) Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumour cells. J Biol Chem 276:37747–37753PubMed

Brahimi-Horn MC, Chiche J, Pouyssegur J (2007) Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol 19:223–229PubMedCrossRef

Buchakjian MR, Kornbluth S (2010) The engine driving the ship: metabolic steering of cell proliferation and death. Nat Rev Mol Cell Biol 11:715–727PubMedCrossRef

Chen H, Yue JX, Yang SH, Ding H, Zhao RW, Zhang S (2009) Overexpression of transketolase-like gene 1 is associated with cell proliferation in uterine cervix cancer. J Exp Clin Cancer Res 28:43PubMedCrossRef

Coy JF, Dressler D, Wilde J, Schubert P (2005) Mutations in the transketolase-like gene TKTL1: clinical implications for neurogenerative diseases, diabetes and cancer. Clin Lab 51:257–273PubMed

Cross NC, Feng L, Bungey J, Goldman JM (1993) Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction. Leuk Lymphoma 11(Suppl 1):39–43PubMedCrossRef

DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7:11–20PubMedCrossRef

Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB (2004) Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64:3892–3899PubMedCrossRef

Foldi M, Stickeler E, Bau L, Kretz O, Watermann D, Gitsch G, Kayser G, zur Hausen A, Coy JF (2007) Transketolase protein TKTL1 overexpression: a potential biomarker and therapeutic target in breast cancer. Oncol Rep 17:841–845PubMed

Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ (2004) Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR–ABL-positive cells. Clin Cancer Res 10:6661–6668PubMedCrossRef

Haaß W, Stehle M, Nittka S, Giehl M, Schrotz-King P, Fabarius A, Hofmann WK, Seifarth W (2012) The proteolytic activity of separase in BCR–ABL-positive cells is increased by imatinib. PLoS ONE 7(8):e42863PubMedCentralPubMedCrossRef

Hehlmann R, Hochhaus A, Baccarani M, European LeukemiaNet (2007) Chronic myeloid leukaemia. Lancet 370:342–350PubMedCrossRef

Hsu PP, Sabatini DM (2008) Cancer cell metabolism: Warburg and beyond. Cell 134:703–707PubMedCrossRef

Hu LH, Yang JH, Zhang DT, Zhang S, Wang L, Cai PC, Zheng JF, Huang JS (2007) The TKTL1 gene influences total transketolase activity and cell proliferation in human colon cancer LoVo cells. Anticancer Drugs 18:427–433PubMedCrossRef

Kim JW, Dang CV (2005) Multifaceted roles of glycolytic enzymes. Trends Biochem Sci 30:142–150PubMedCrossRef

Kim JW, Dang CV (2006) Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res 66:8927–8930PubMedCrossRef

Klawitter J, Kominsky DJ, Brown JL, Klawitter J, Christians U, Leibfritz D, Melo JV, Eckhardt SG, Serkova NJ (2009) Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. Br J Pharmacol 158:588–600PubMedCrossRef

Kohrenhagen N, Voelker HU, Schmidt M, Kapp M, Krockenberger M, Frambach T, Dietl J, Kammerer U (2008) Expression of transketolase-like 1 (TKTL1) and p-Akt correlates with the progression of cervical neoplasia. J Obstet Gynaecol Res 34:293–300PubMedCrossRef

Krockenberger M, Honig A, Rieger L, Coy JF, Sutterlin M, Kappehorn M, Dietl J, Kammerer U (2007) Transketolase-like 1 expression correlates with subtypes of ovarian cancer and the presence of distant metastases. Int J Gynecol Cancer 17:101–106PubMedCrossRef

Langbein S, Zerilli M, zur Hausen A, Staiger W, Rensch-Boschert K, Lukan N, Popa J, Ternullo MP, Steidler A, Weiss C, Grobholz R, Willeke F, Alken P, Stassi G, Schubert P, Coy JF (2006) Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer 94:578–585PubMedCentralPubMedCrossRef

Langbein S, Frederiks WM, zur Hausen A, Popa J, Lehmann J, Weiss C, Alken P, Coy JF (2008) Metastasis is promoted by a bioenergetic switch: new targets for progressive renal cell cancer. Int J Cancer 122:2422–2428PubMedCrossRef

Mueller MC, Erben P, Saglio G, Gottardi E, Nyvold CG, Schenk T, Ernst T, Lauber S, Kruth J, Hehlmann R, Hochhaus A, European LeukemiaNet (2008) Harmonization of BCR–ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 22:96–102CrossRef

O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, for the IRIS Investigators BJD (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994–1004PubMedCrossRef

Radich JP (2007) The biology of CML blast crisis. Hematol Am Soc Hematol Educ Program 2007(1):384–391

Schmidt M, Kammerer U, Segerer S, Cramer A, Kohrenhagen N, Dietl J, Voelker HU (2008) Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF. Eur J Obstet Gynecol Reprod Biol 139:72–78PubMedCrossRef

Schwaab J, Horisberger K, Strobel P, Bohn B, Gencer D, Kahler G, Kienle P, Post S, Wenz F, Hofmann WK, Hofheinz RD, Erben P (2011) Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. BMC Cancer 11:363PubMedCentralPubMedCrossRef

Shaw RJ (2006) Glucose metabolism and cancer. Curr Opin Cell Biol 18:598–608PubMedCrossRef

Sillaber C, Mayerhofer M, Agis H, Sagaster V, Mannhalter C, Sperr WR, Geissler K, Valent P (2003) Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts. Wien Klin Wochenschr 115:485–504PubMedCrossRef

Staiger WI, Coy JF, Grobholz R, Hofheinz RD, Lukan N, Post S, Schwarzbach MH, Willeke F (2006) Expression of the mutated transketolase TKTL1, a molecular marker in gastric cancer. Oncol Rep 16:657–661PubMed

Van der Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 3234:1029–1033CrossRef

Volker HU, Scheich M, Schmausser B, Kammerer U, Eck M (2007) Overexpression of transketolase TKTL1 is associated with shorter survival in laryngeal squamous cell carcinomas. Eur Arch Otorhinolaryngol 264:1431–1436PubMedCrossRef

Volker HU, Hagemann C, Coy J, Wittig R, Sommer S, Stojic J, Haubitz I, Vince GH, Kammerer U, Monoranu CM (2008) Expression of transketolase-like 1 and activation of akt in grade IV glioblastomas compared with grades II and III astrocytic gliomas. Am J Clin Pathol 130:50–57PubMedCrossRef

Warburg O, Poesener K, Negelein E (1924) Uber den Stoffwechsel der Carzinomzelle. Biochem Z 152:309–344

Wu HT, Allie N, Myer L, Govender D (2009) Anaplastic nephroblastomas express transketolaselike enzyme 1. J Clin Pathol 62:460–463PubMedCrossRef

Xu X, zur Hausen A, Coy JF, Lochelt M (2009) Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells. Int J Cancer 124:1330–1337PubMedCrossRef

Yuan W, Wu S, Guo J, Chen Z, Ge J, Yang P, Hu B, Chen Z (2010) Silencing of TKTL1 by siRNA inhibits proliferation of human gastric cancer cells in vitro and in vivo. Cancer Biol Ther 9:710–716PubMedCrossRef

Zerilli M, Amato MC, Martorana A, Cabibi D, Coy JF, Cappello F, Pompei G, Russo A, Giordano C, Rodolico V (2008) Increased expression of transketolase-like-1 in papillary thyroid carcinomas smaller than 1.5 cm in diameter is associated with lymph-node metastases. Cancer 113:936–944PubMedCrossRef

Zhang S, Yang JH, Guo CK, Pcheng C (2007) Gene silencing of TKTL1 by RNAi inhibits cell proliferation in human hepatoma cells. Cancer Lett 253:108–114PubMedCrossRef

Zhao F, Mancuso A, Bui TV, Tong X, Gruber JJ, Swider CR, Sanchez PV, Lum JJ, Sayed N, Melo JV, Perl AE, Carroll M, Tuttle SW, Thompson CB (2010) Imatinib resistance associated with BCR–ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming. Oncogene 29:2962–2972PubMedCentralPubMedCrossRef

Titel: Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML)
verfasst von: M. Philipp
J. Schwaab
C. T. Dietz
B. Hanfstein
L. Kalmanti
U. Munjal
M. Mossner
D. Nowak
W. Seifarth
W. K. Hofmann
A. Hochhaus
M. C. Müller
P. Erben
Publikationsdatum: 01.03.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 3/2014
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-013-1579-x

Springer Medizin

Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML)